LS
HRMY icon

Livforsakringsbolaget Skandia’s Harmony Biosciences HRMY Stock Holding History

Livforsakringsbolaget Skandia’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,600
Closed -$396K – 477
2025
Q4 		$396K Sell
10,600
-40,800
-79% -$1.34M 0.02% 251
2025
Q3 		$1.41M Sell
51,400
-10,300
-17% -$355K 0.06% 164
2025
Q2 		$1.95M Buy
61,700
+10,900
+21% +$351K 0.08% 153
2025
Q1 		$1.68M Buy
50,800
+3,100
+6% +$111K 0.1% 148
2024
Q4 		$1.64M Buy
47,700
+2,800
+6% +$96.2K 0.09% 152
2024
Q3 		$1.8M Buy
44,900
+20,600
+85% +$724K 0.1% 148
2024
Q2 		$733K Hold
24,300
– – 0.06% 183
2024
Q1 		$814K Buy
24,300
+17,800
+274% +$571K 0.07% 186
2023
Q4 		$210K Buy
+6,500
New +$181K 0.02% 239

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Livforsakringsbolaget Skandia's HRMY Position: Q1 2026 in Review

Livforsakringsbolaget Skandia sold out of Harmony Biosciences (HRMY) in Q1 2026, closing a stake of 10,600 shares — an estimated $396K sold.

Livforsakringsbolaget Skandia first reported a position in HRMY in Q4 2023 and held it in 9 quarters. The position peaked at $1.95M in Q2 2025. 310 funds tracked by Wall St. Rank hold HRMY as of Q1 2026.

  • Livforsakringsbolaget Skandia reported no remaining Harmony Biosciences position as of Q1 2026 after selling out during the quarter.
  • Livforsakringsbolaget Skandia sold 10,600 Harmony Biosciences shares in Q1 2026, an estimated $396K.
  • Livforsakringsbolaget Skandia first reported a position in Harmony Biosciences in Q4 2023 and held it in 9 quarters.
  • Livforsakringsbolaget Skandia's Harmony Biosciences position peaked at $1.95M in Q2 2025.
  • 310 funds tracked by Wall St. Rank held Harmony Biosciences as of Q1 2026.

Based on Livforsakringsbolaget Skandia's 13F filing for Q1 2026, filed 5 May 2026.